Genoray Co Ltd

Genoray maintains a debt-to-equity ratio of 0.4, indicating a relatively conservative capital structure with total liabilities of ₩46.7 billion and equity of ₩84.5 billion. The company holds ₩13.8 billion in cash and equivalents, but its net cash position is negative after subtracting long-term debt of ₩34.0 billion, signaling potential liquidity constraints. Free cash flow of ₩5.5 billion and operating cash flow of ₩5.3 billion suggest the company generates sufficient cash to support operations and limited reinvestment. Profitability metrics reveal mixed performance. Return on equity (ROE) of 0.9% and return on assets (ROA) of 0.58% fall below typical thresholds for capital-intensive medical equipment firms, indicating underperformance relative to industry expectations. Gross profit of ₩41.7 billion represents 38.6% of revenue, but operating income is negative at ₩243 million, highlighting inefficiencies in cost control or pricing. The company’s revenue is concentrated in its core X-ray imaging products, with no disclosed geographic diversification beyond South Korea. This lack of segment or geographic transparency limits visibility into growth drivers or risk exposure. Recent financial trends show a decline in operating income despite revenue of ₩108.0 billion. Capital expenditures of ₩1.4 billion suggest modest reinvestment, but the absence of clear growth segments or geographic expansion plans raises questions about long-term scalability. Liquidity risk is elevated due to the negative net cash position, while dilution risk remains low based on unchanged basic and diluted shares outstanding of 12.7 million. No recent filings or transcripts disclose material events, but the operating loss and debt load warrant closer monitoring of cash flow sustainability.